TY - JOUR
T1 - Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems
AU - Mehrotra, Sonal
AU - Salwa, A.
AU - Kumar, Lalit
N1 - Publisher Copyright:
© 2023 by Begell House
PY - 2023
Y1 - 2023
N2 - Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.
AB - Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.
UR - http://www.scopus.com/inward/record.url?scp=85147721012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147721012&partnerID=8YFLogxK
U2 - 10.1615/CritRevTherDrugCarrierSyst.2022042927
DO - 10.1615/CritRevTherDrugCarrierSyst.2022042927
M3 - Review article
C2 - 36749082
AN - SCOPUS:85147721012
SN - 0743-4863
VL - 40
SP - 1
EP - 46
JO - Critical Reviews in Therapeutic Drug Carrier Systems
JF - Critical Reviews in Therapeutic Drug Carrier Systems
IS - 3
ER -